AVI BioPharma, Inc. (NASDAQ:AVII)

CAPS Rating: 4 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

Recs

0
Player Avatar Rahasia (< 20) Submitted: 9/3/2009 5:45:53 PM : Outperform Start Price: $1.81 AVII Score: -91.91

Great stock.

Report this Post Reply

Featured Broker Partners


Advertisement